Kite Pharma Completes Filing for CAR-T Therapy with FDA – Nasdaq
Nasdaq |
Kite Pharma Completes Filing for CAR–T Therapy with FDA
Nasdaq We note that axicabtagene ciloleucel is Kite Pharma's anti-CD19 chimeric antigen receptor (CAR) T cell therapy. The BLA is for the treatment for patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL) who are ineligible for … Kite keeps pressure on Novartis with CAR–T filing Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR–T Trial of Axicabtagene Ciloleucel in … |
